Benzothiepin-derived molecular scaffolds for estrogen receptor modulators: synthesis and antagonistic effects in breast cancer cells

References

• MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 1998; 50(2)151–196
   PubMed Web of Science ®Google Scholar
• Jordan VC. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. J Med Chem 2003; 46(6)883–908, 1. Receptor interactions
   PubMedGoogle Scholar
• Jordan VC. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. J Med Chem 2003; 46(7)1081–1111, 2. Clinical considerations and new agents
   PubMed Web of Science ®Google Scholar
• Ariazi EA, Ariazi JL, Cordera F, Jordan VC. Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem 2006; 6(3)181–202
   PubMed Web of Science ®Google Scholar
• Gustafsson JA. Estrogen receptor beta-a new dimension in estrogen mechanism of action. J Endocrinol 1999; 163(3)379–383
   PubMed Web of Science ®Google Scholar
• Pearce ST, Jordan VC. The biological role of estrogen receptors alpha and beta in cancer. Crit Rev Oncol Hematol 2004; 50(1)3–22
   PubMedGoogle Scholar
• Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 2004; 11(3)537–551
   PubMed Web of Science ®Google Scholar
• Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998; 95(7)927–937
   PubMed Web of Science ®Google Scholar
• Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389(6652)753–758
   PubMed Web of Science ®Google Scholar
• Pike AC, Brzozowski AM, Walton J, Hubbard RE, Thorsell AG, Li YL, Gustafsson JA, Carlquist M. Structural insights into the mode of action of a pure antiestrogen. Structure 2001; 9(2)145–153
   PubMedGoogle Scholar
• Wu YL, Yang X, Ren Z, McDonnell DP, Norris JD, Willson TM, Greene GL. Structural basis for an unexpected mode of SERM-mediated ER antagonism. Mol Cell 2005; 18(4)413–424
   PubMed Web of Science ®Google Scholar
• Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engstrom O, Ljunggren J, Gustafsson JA, Carlquist M. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. Embo J 1999; 18(17)4608–4618
   PubMed Web of Science ®Google Scholar
• Lloyd DG, Buenemann CL, Todorov NP, Manallack DT, Dean PM. Scaffold hopping in de novo design. Ligand generation in the absence of receptor information. J Med Chem 2004; 47(3)493–496
   PubMed Web of Science ®Google Scholar
• Singh MM. Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders. Med Res Rev 2001; 21(4)302–347
   PubMed Web of Science ®Google Scholar
• Labrie F, Labrie C, Belanger A, Simard J, Gauthier S, Luu-The V, Merand Y, Giguere V, Candas B, Luo S, Martel C, Singh SM, Fournier M, Coquet A, Richard V, Charbonneau R, Charpenet G, Tremblay A, Tremblay G, Cusan L, Veilleux R. EM-652 (SCH57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J Steroid Biochem Mol Biol 1999; 69(1-6)51–84
   PubMedGoogle Scholar
• Jain N, Kanojia RM, Xu J, Jian-Zhong G, Pacia E, Lai MT, Du F, Musto A, Allan G, Hahn D, Lundeen S, Sui Z. Novel chromene-derived selective estrogen receptor modulators useful for alleviating hot flushes and vaginal dryness. J Med Chem 2006; 49(11)3056–3059
   PubMedGoogle Scholar
• Kim S, Wu JY, Birzin ET, Frisch K, Chan W, Pai LY, Yang YT, Mosley RT, Fitzgerald PM, Sharma N, Dahllund J, Thorsell AG, DiNinno F, Rohrer SP, Schaeffer JM, Hammond ML. Estrogen receptor ligands. II. Discovery of benzoxathiins as potent, selective estrogen receptor alpha modulators. J Med Chem 2004; 47(9)2171–2175
   PubMedGoogle Scholar
• Sibley R, Hatoum-Mokdad H, Schoenleber R, Musza L, Stirtan W, Marrero D, Carley W, Xiao H, Dumas J. A novel estrogen receptor ligand template. Bioorg Med Chem Lett 2003; 13(11)1919–1922
   PubMedGoogle Scholar
• Wallace OB, Lauwers KS, Dodge JA, May SA, Calvin JR, Hinklin R, Bryant HU, Shetler PK, Adrian MD, Geiser AG. A selective estrogen receptor modulator for the treatment of hot flushes. J Med Chem 2006; 49(3)843–846
   PubMedGoogle Scholar
• Lloyd DG, Hughes RB, Zisterer DM, Williams DC, Fattorusso C, Catalanotti B, Campiani G, Meegan MJ. Benzoxepin-derived estrogen receptor modulators: a novel molecular scaffold for the estrogen receptor. J Med Chem 2004; 47(23)5612–5615
   PubMedGoogle Scholar
• Sarkhel S, Sharon A, Trivedi V, Maulik PR, Singh MM, Venugopalan P, Ray S. Structure-based drug design: Synthesis, crystal structure, biological evaluation and docking studies of mono- and bis-benzo[b]oxepines as non-steroidal estrogens. Bioorg Med Chem 2003; 11(23)5025–5033
   PubMedGoogle Scholar
• Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor transcription and transactivation: Estrogen receptor alpha and estrogen receptor beta: Regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res 2000; 2(5)335–344
   PubMedGoogle Scholar
• Nioche JYD, J., Festal D. Synthesis and structure-activity relationships of new ACAT inhibitors. Eur J Med Chem 1995; 30(5)377–385
   Google Scholar
• Littlefield BA, Gurpide E, Markiewicz L, McKinley B, Hochberg RB. A simple and sensitive microtiter plate estrogen bioassay based on stimulation of alkaline phosphatase in Ishikawa cells: Estrogenic action of delta 5 adrenal steroids. Endocrinology 1990; 127(6)2757–2762
   PubMedGoogle Scholar
• ACD/Chemsketch v10: Advanced Chemistry Labs., http://wwwacdlabscom/download/chemskhtml
   Google Scholar
• OMEGA 2.1: distributed by Openeye Scientific Software
   Google Scholar
• Molecular Operating Environment (MOE): Developed and distributed by Chemical Computing Group., (http://wwwchemcompcom)
   Google Scholar
• FRED (version 2.11): Developed and distributed by Openeye Scientific Software., http://wwweyesopencom
   Google Scholar
• Sybyl6.91: Distributed by Tripos Inc http://wwwtriposcom
   Google Scholar
• Szybki: Developed and distributed by Openeye Scientific Software., http://wwweyesopencom
   Google Scholar
• Teo CC, Kon OL, Sim KY, Ng SC. Synthesis of 2-(p-chlorobenzyl)-3-aryl-6-methoxybenzofurans as selective ligands for antiestrogen-binding sites. Effects on cell proliferation and cholesterol synthesis. J Med Chem 1992; 35(8)1330–1339
   PubMedGoogle Scholar
• Shani J, Gazit A, Livshitz T, Biran S. Synthesis and receptor-binding affinity of fluorotamoxifen, a possible estrogen-receptor imaging agent. J Med Chem 1985; 28(10)1504–1511
   PubMedGoogle Scholar
• Yang DJ, Tewson T, Tansey W, Kuang LR, Reger G, Cherif A, Wright KC, Moult RG, Tilbury RS, Chu K, Kim EE, Wallace S. Halogenated analogues of tamoxifen: Synthesis, receptor assay, and inhibition of MCF7 cells. J Pharm Sci 1992; 81(7)622–625
   PubMedGoogle Scholar
• McCague R, Leclercq G, Jordan VC. Nonisomerizable analogues of (Z)- and (E)-4-hydroxytamoxifen. Synthesis and endocrinological properties of substituted diphenylbenzocycloheptenes. J Med Chem 1988; 31(7)1285–1290
   PubMedGoogle Scholar
• Acton D, Hill G, Tait BS. Tricyclic triarylethylene antiestrogens: Dibenz[b,f]oxepins, dibenzo[b,f]thiepins, dibenzo[a,e]cyclooctenes, and dibenzo[b,f]thiocins. J Med Chem 1983; 26(8)1131–1137
   PubMedGoogle Scholar
• Catherino WH, Wolf DM, Jordan VC. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog. Mol Endocrinol 1995; 9(8)1053–1063
   PubMedGoogle Scholar
• Lloyd DG, Smith HM, O' Sullivan T, Zisterer DM, Meegan MJ. Synthesis, Structure-Activity Relationships and Antagonistic Effects in Human MCF-7 Breast Cancer Cells of Flexible Estrogen Receptor Modulators. Medicinal Chemistry 2005; 1(4)335–353
   PubMedGoogle Scholar
• Sobolev V, Sorokine A, Prilusky J, Abola EE, Edelman M. Automated analysis of interatomic contacts in proteins. Bioinformatics 1999; 15(4)327–332
   PubMed Web of Science ®Google Scholar
• Mewshaw RE, Edsall RJ, Jr, Yang C, Manas ES, Xu ZB, Henderson RA, Keith JC, Jr, Harris HA. ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem 2005; 48(12)3953–3979
   PubMedGoogle Scholar
• Malamas MS, Manas ES, McDevitt RE, Gunawan I, Xu ZB, Collini MD, Miller CP, Dinh T, Henderson RA, Keith JC, Jr. Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem 2004; 47(21)5021–5040
   PubMedGoogle Scholar
• Yang C, Edsall R, Jr, Harris HA, Zhang X, Manas ES, Mewshaw RE. ERbeta ligands. Part 2: Synthesis and structure-activity relationships of a series of 4-hydroxy-biphenyl-carbaldehyde oxime derivatives. Bioorg Med Chem 2004; 12(10)2553–2570
   PubMedGoogle Scholar